Clinical Trial Results

Molecular Alterations Associated With Improved Outcome in Patients With Glioblastoma Treated With Tumor-Treating Fields Bookmark

Do molecular biomarkers have any role in treating glioblastoma (GBM)? As outlined in this scientific research report from the academic journal Neuro-Oncology Research Advances, a recent study found that 3 biomarkers were correlated with very great outcome differences for people treated with tumor-treating (electrical) fields.

.

.

‘Clinically Meaningful’ Improvement in SCLC Patients With Pembrolizumab/Chemo Combo Bookmark

As reported by MedPage Today, long-term results from a clinical trial suggest that a combination of the drug pembrolizumab plus chemotherapy is better than chemo alone for small cell lung cancer (SCLC). But unfortunately, most patients who received the combo did not benefit significantly, and biomarkers are very much needed to identify patients whose cancers will respond well.

.

Good for Bladder Cancer, Better for Kidney Cancer Bookmark

This article from the National Cancer Institute’s Center for Cancer Research outlines new clinical trial results showing that combining the drugs cabozantinib and nivolumab doubled progression-free survival for people with advanced renal cell carcinoma compared to giving cabozantinib alone.

.

Adagrasib in Previously Treated Patients With KRAS G12C–Mutated Advanced NSCLC Bookmark

As reported by The ASCO Post, the drug adagrasib has shown some promising results in a clinical trial for people with advanced non-small cell lung cancer (NSCLC) with a KRAS-g12c mutation whose cancer progressed after prior treatment. The U.S. Food and Drug Administration (FDA) allows adagrasib to be given to people whose cancer has a KRAS-g12c mutation through expanded access.

.

Relatlimab and Nivolumab vs Nivolumab in Previously Untreated Metastatic/Unresectable Melanoma: Overall Survival and Response From RELATIVITY-047 Bookmark

According to MedPage Today, the addition of the drug relatlimab to treatment with nivolumab improved survival for people with advanced melanoma in a clinical trial.

.

New Clinical Trial Results for Pembrolizumab in Triple-Negative Breast Cancer Bookmark

As reported in the medical research journal The Lancet, adding the drug pembrolizimab (Keytruda) to chemotherapy increased progression-free survival—both clinically and statistically—for clinical trial participants with advanced breast cancer.

.

Immunotherapy Before Targeted Therapy Extends OS in Metastatic Melanoma Bookmark

As reported by Healio, immunotherapy followed by targeted therapy improved overall survival in a clinical trial with metastatic melanoma patients.

.

Olaparib Shows Promise for Castrate-Resistant Prostate Cancer Bookmark

This Business Wire press release announces results from a clinical trial indicating that adding the drug olaparib (brand name Lynparza) to treatment for castrate-resistant prostate cancer enhanced disease-free progression, regardless of biomarker status.

.

Transarterial Radioembolization in Patients With Unresectable Colorectal Cancer Liver Metastases Bookmark

This scientific editorial article from the Journal of Clinical Oncology discusses results from a clinical trial suggesting that addition of a treatment called transarterial radioembolization to standard treatment was not effective for people with colorectal cancer liver metastases that cannot be removed by surgery.

.

Results from Clinical Trial of Veliparib for People with Unmethylated Glioblastoma Bookmark

This scientific report from Neuro-Oncology outlines findings from a large, randomized clinical trial showing that the drug veliparib (a kind of drug known as a PARP inhibitor) added to radiotherapy and temozolomide did not improve progression-free survival in unmethylated glioblastoma.

.